Haier Biotech said at the 2026 third quarter results briefing that the company currently has targets for mergers and acquisitions, which mainly focus on “core equipment and reagent consumables for biological manufacturing” and “high-point card position technology extension to support the expansion of new scenarios”. In the medium to long term, the company will continue to expand around the three growth curves. Through “endogenous+epitaxial” two-wheel drive, the company will gradually grow from a product-driven equipment provider to a technology-driven scientific service platform, and strive to achieve the goal of not less than 40% of M&A revenue within 3 years.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.